Лекарства за имунотерапия и таргетна терапия (в онкологията)
Лекарствена молекула Таргет Одобрени индикации (FDA)
=================== ========== ===========================
Abagovomab Рак на яйчника
Abatacept CD28, CD80 and CD86
Abemaciclib (Verzenios) CDK4 / CDK4 Ретинобластом/ положителен за хормонален рецептор (HR), отрицателен за рецептор за човешки епидермален растежен фактор 2 (HER2) локално авансирал или метастатичен рак на млечната жлеза
Ado-trastuzumab emtansine (Kadcyla) HER2 (ERBB2/neu) Рак на гърдата (HER2+)
Afatinib (Gilotrif) EGFR (HER1/ERBB1), HER2 (ERBB2/neu) Недребноклетъчен рак на белия дроб ( с EGFR exon 19 deletions или exon 21 substitution (L858R) mutations)
Aldesleukin (Proleukin) Бъбречноклетъчен карцином /Mеланом
Alectinib (Alecensa) ALK Недребноклетъчен рак на белия дроб ( с ALK fusion)
Alemtuzumab (Campath) CD52 B-клетъчна хронична лимфоцитна левкемия (cell chronic lymphocytic leukemia)
Anlotinib (receptor tyrosine kinase (RTK) inhibitor) Карцином на яйчника
Atezolizumab (Tecentriq) PD-L1 Уротелен карцином /Недребноклетъчен рак на белия дроб
Avelumab (Bavencio) D-L1 Меркел-клетъчен карцином /Уротелиален карцином
Axitinib (Inlyta) KIT, PDGFRβ, VEGFR1/2/3 Бъбречноклетъчен карцином
Apatinib (Aitan) VEGFR-2 Карцином на стомаха (при китайци)
–––––––––––––––––––––––––––––––––––––––––
Belimumab (Benlysta) BAFF Лупус еритематозус
Belinostat (Beleodaq) HDAC Периферна Т-клетъчна лимфома (Peripheral T-cell lymphoma)
Bevacizumab (Avastin) VEGF ligand Карцином на маточната шийка/ Колоректален карцином /Карцином на фалопиевите тръби/Глиобластом/ НДКРБД /Карцином на яйчника/ Карцином на перитонеума/Бъбречноклетъчен карцином
Blinatumomab (Blincyto) CD19/CD3 Остра лимфобластна левкемия (precursor B-cell)
Bortezomib (Velcade) Proteasome Мултиплен миелом/ Мантелно-клетъчен лимфом
Bosutinib (Bosulif) ABL Chronic myelogenous leukemia (Philadelphia chromosome positive)
Brentuximab vedotin (Adcetris) CD30 Hodgkin lymphoma /Anaplastic large cell lymphoma
Brigatinib (Alunbrig) ALK НДКРБД (ALK+)
–––––––––––––––––––––––––––––––––––––––––-
Cabozantinib (Cabometyx, Cometriq [capsule]) FLT3, KIT, MET, RET, VEGFR2 Medullary thyroid cancer /Бъбречноклетъчен карцином
Canakinumab (Ilaris) IL-1β Juvenile idiopathic arthritis /Cryopyrin-associated periodic syndromes
Camrelizumab PD1 Хепатицелуларна карцинома, Ходжкинов лимфом
Carfilzomib (Kyprolis) Proteasome Мултиплен миелом
Ceritinib (Zykadia) ALK НДКРБД ( с ALK fusion)
Cetuximab (Erbitux) EGFR (HER1/ERBB1) Колоректален карцином (KRAS wild type) Squamous cell cancer of the head and neck
Cemiplimab (Libtayo) PD-1 metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, бял дроб, миелом
Cobimetinib (Cotellic) MEK Меланом (с BRAF V600E or V600K mutation)
Copanlisib (ALIQOPA) adult patients with relapsed follicular lymphoma (FL)
Crizotinib (Xalkori) ALK, MET, ROS1 Non-small cell lung cancer (with ALK fusion or ROS1 gene alteration)
–––––––––––––––––––––––––––––––––––––––––
Dabrafenib (Tafinlar) BRAF Mеланом (with BRAF V600 mutation) Non-small cell lung cancer (with BRAF V600E mutation)
Daratumumab (Darzalex) CD38 Multiple myeloma
Dasatinib (Sprycel) ABL Chronic myelogenous leukemia (Philadelphia chromosome positive) Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Denosumab (Xgeva) RANKL Giant cell tumor of the bone
Dinutuximab (Unituxin) B4GALNT1 (GD2) Pediatric neuroblastoma
Durvalumab (Imfinzi) PD-L1 Urothelial carcinoma //Non-small cell lung cancer
–––––––––––––––––––––––––––––––––––––––––
Elotuzumab (Empliciti) SLAMF7 (CS1/CD319/CRACC) Multiple myeloma
Enasidenib (Idhifa) IDH2 Acute myeloid leukemia (with IDH2 mutation)
Erlotinib (Tarceva) EGFR (HER1/ERBB1) Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations) Pancreatic cancer mTOR Pancreatic, gastrointestinal, or lung origin neuroendocrine tumor Renal cell carcinoma Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis Breast cancer (HR+, HER2-)
Erdafitinib (Balversa) FGFR kinase inhibitor Авансирал или метастазирал уропелиален карцином
Entrеctenib TKI /Trk Карциним на бял дроб
–––––––––––––––––––––––––––––––––––––––––
Gefitinib (Iressa) EGFR (HER1/ERBB1) Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
Glesatinib MET, Axl Non-Small Cell Lung Cancer
Gilteritinib AML
–––––––––––––––––––––––––––––––––––––––––
Ibritumomab tiuxetan (Zevalin) CD20 Non-Hodgkin’s lymphoma
Ibrutinib (Imbruvica) BTK Mantle cell lymphoma Chronic lymphocytic leukemia Waldenstrom’s macroglobulinemia
Idelalisib (Zydelig) PI3Kδ Chronic lymphocytic leukemia Follicular B-cell non-Hodgkin lymphoma Small lymphocytic lymphoma
Imatinib (Gleevec) KIT, PDGFR, ABL GI stromal tumor (KIT+) Dermatofibrosarcoma protuberans Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML
Ipilimumab (Yervoy) CTLA-4 Melanoma Renal cell carcinoma
Ixazomib (Ninlaro) Proteasome Multiple Myeloma
–––––––––––––––––––––––––––––––––––––––––-
Lapatinib (Tykerb) HER2 (ERBB2/neu), EGFR (HER1/ERBB1) Breast cancer (HER2+)
Lenvatinib (Lenvima) VEGFR2 Renal cell carcinoma /Thyroid cancer
Larotrectinib (Vitrakvi) inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC Сарком и metastatic solid tumors with NTRK fusion
–––––––––––––––––––––––––––––––––––––––––
Midostaurin (Rydapt) FLT3 acute myeloid leukemia (FLT3+)
––––––––––––––––––––––––––––––––––––––––-
Necitumumab (Portrazza) EGFR (HER1/ERBB1) Squamous non-small cell lung cancer
Neratinib (Nerlynx) HER2 (ERBB2/neu) Breast cancer (HER2 overexpressed/amplified)
Nilotinib (Tasigna) ABL Chronic myelogenous leukemia (Philadelphia chromosome positive)
Niraparib (Zejula) PARP Ovarian cancer Fallopian tube cancer Peritoneal cancer
Nivolumab (Opdivo) PD-1 Colorectal cancer (dMMR and MSI-H) /Head and neck squamous cell carcinoma /Hepatocellular carcinoma /Hodgkin lymphoma/ Melanoma /Non-small cell lung cancer /Renal cell carcinoma/Urothelial carcinoma
––––––––––––––––––––––––––––––––––––––––
Obinutuzumab (Gazyva) CD20 Chronic lymphocytic leukemia// Follicular lymphoma
Ofatumumab (Arzerra, HuMax-CD20) CD20 Chronic lymphocytic leukemia
Olaparib (Lynparza) PARP Ovarian cancer (with BRCA mutation)
Olaratumab (Lartruvo) PDGFRα Soft tissue sarcoma
Osimertinib (Tagrisso) EGFR Non-small cell lung cancer (with EGFR T790M mutation)
–––––––––––––––––––––––––––––––––––––––––-
Palbociclib (Ibrance) CDK4, CDK6 Breast cancer (HR+, HER2-)
Panitumumab (Vectibix) EGFR (HER1/ERBB1) Colorectal cancer (KRAS wild type)
Panobinostat (Farydak) HDAC Multiple myeloma
Pazopanib (Votrient) VEGFR, PDGFR, KIT Renal cell carcinoma
Pembrolizumab (Keytruda) PD-1
Classical Hodgkin lymphoma
Colorectal cancer (MSI-H/dMMR)
Gastric cancer
Melanoma
Non-small cell lung cancer (PD-L1+)
Head and neck squamous cell carcinoma
Urothelial cancer
Solid tumors (MSI-H/dMMR)
Pertuzumab (Perjeta) HER2 (ERBB2/neu) Breast cancer (HER2+)
Ponatinib (Iclusig) ABL, FGFR1-3, FLT3, VEGFR2 Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive)
Pralsetinib inhibitor of RET fusison НКРБД, карцином на щитовидната жлеза
–––––––––––––––––––––––––––––––––––––––––-
Ramucirumab (Cyramza) VEGFR2 Colorectal cancer Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma Non-small cell lung cancer
Regorafenib (Stivarga) KIT, PDGFRβ, RAF, RET, VEGFR1/2/3 Colorectal cancer Gastrointestinal stromal tumors //Hepatocellular carcinoma
Ribociclib (Kisqali) CDK4, CDK6 Breast cancer (HR+, HER2-)
Rituximab (Rituxan, Mabthera) CD20 Non-Hodgkin’s lymphoma Chronic lymphocytic leukemia Rheumatoid arthritis Granulomatosis with polyangiitis
Rituximab/hyaluronidase human (Rituxan Hycela) CD20 Chronic lymphocytic leukemia Diffuse large B-cell lymphoma Follicular lymphoma
Romidepsin (Istodax) HDAC Cutaneous T-cell lymphoma Peripheral T-cell lymphoma
Rucaparib (Rubraca) PARP Ovarian cancer (with BRCA mutation)
Ruxolitinib (Jakafi) JAK1/2 Myelofibrosis
Savolitinib inhibitor of c-Met Бъбречен карцином, НДКРБД, аденокарцином
Selumetinib MEK 1/2 inhibitor Pilocytic astrocytoma
Siltuximab (Sylvant) IL-6 Multicentric Castleman’s disease
Sipuleucel-T (Provenge) Prostate cancer
Sintilimab (Tyvyt) human IgG4 monoclonal antibody Hodgkin’s lymphoma, non-small cell lung cancer and oesophageal cancer, in China
Sonidegib (Odomzo) Smoothened Basal cell carcinoma
Sorafenib (Nexavar) VEGFR, PDGFR, KIT, RAF Hepatocellular carcinoma Renal cell carcinoma Thyroid carcinoma
–––––––––––––––––––––––––––––––––––––––––
Temsirolimus (Torisel) mTOR Renal cell carcinoma
Tepotinib MET alterations include MET-exon 14 skipping mutations (METex14+) НДКРБД
Tocilizumab (Actemra) IL-6R Rheumatoid arthritis Juvenile idiopathic arthritis
Tofacitinib (Xeljanz) JAK3 Rheumatoid arthritis
Tositumomab (Bexxar) CD20 Non-Hodgkin’s lymphoma
Trametinib (Mekinist) MEK Melanoma (with BRAF V600 mutation) Non-small cell lung cancer (with BRAF V600E mutation)
Trastuzumab (Herceptin) HER2 (ERBB2/neu) Breast cancer (HER2+) Gastric cancer (HER2+)
Trebananinb Endothelial cell-selective Tie2 Карцином на яйчника
Tukatinib PARP Рак на гърдата
–––––––––––––––––––––––––––––––––––––––––
Vandetanib (Caprelsa) EGFR (HER1/ERBB1), RET, VEGFR2 Medullary thyroid cancer
Vemurafenib (Zelboraf) BRAF Melanoma (with BRAF V600 mutation)
Venetoclax (Venclexta) BCL2 Chronic lymphocytic leukemia (with 17p deletion)
Veliparib PARP inhibitor Млечна жлеза и яйчник
Vismodegib (Erivedge) PTCH, Smoothened Basal cell carcinoma
Vorinostat (Zolinza) HDAC Cutaneous T-cell lymphoma
–––––––––––––––––––––––––––––––––––––––––-
Ziv-aflibercept (Zaltrap) PIGF, VEGFA/B Colorectal cancer